Reported cases of squamous cell carcinoma of the extrahepatic bile duct
| Year | Author | Age | Sex | Location | Initial staging | Histological type | Depth | Metastasis | Operation | Postoperative treatment | Prognosis after surgery |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1930 | Cabot1 | 58 | M | P | IVB | NA | NA | S in liver | Autopsy | – | NA |
| 1978 | Burger4 | 24 | F | D | NA | Mod | NA | M in liver | PD | CPM/DOX/MTX/PCZ | 8M dead |
| 1979 | Gulsrud5 | 68 | M | NA | NA | Well | NA | – | Chole and T tube | – | 6M dead |
| 1980 | Aranha6 | 58 | F | P | IVB | Por | NA | S in liver | Chole and T tube | Radiation | 3M dead |
| 1990 | Clements7 | 73 | M | P | NA | Well | NA | S in LN (N2), peritoneal | BS | – | NA |
| 2004 | Gatof8 | 86 | F | P | NA | NA | NA | NA | Chole and BS | Radiation | 18M dead* |
| 2004 | La Greca9 | 61 | F | P | II | Por | T2a | Neural invasion→M in peritoneal | Exc of BD | – | 14M dead |
| 2005 | Sewkani10 | 60 | M | D | IB | Well | T2 | – | PD | – | NA |
| 2008 | Abbas11 | 86 | F | P | II | Mod | T2b | – | Ext lt hep | Radiation | 18M alive |
| 2008 | Price12 | 41 | F | P | IVA | NA | T4 | Direct extension to PV, invasion in duodenum | GJ and BS | Chemotherapy+radiation | NA |
| 2011 | Yamana13 | 66 | M | P | IVA | Well | T4 | S in LN (N1), partly invaded to the PV and liver, M in liver | Ext rt hep | CDDP/5-FU→GEM/S-1 | 12M dead |
| 2015 | Yoo14 | 67 | M | P | IIIB | Well | T1 | S in LN (N1)→M in liver | PPPD | – | 8M dead |
| 2016 | Goto15 | 77 | F | P | IIIA | Por | T3 | Local recurrence | PPPD | GEM | 32M dead |
| 2016 | Our case | 78 | M | D | IIB | Mod | T1 | S in LN (N1), neural, lymphatic invasion→M in LN (N2) | SSPPD | S-1/CDDP | 16M alive |
*Prognosis after diagnosis.
5-FU, 5-fluorouracil; BD, bile duct; BS, biliary stent; CDDP, cisplatin; Chole, cholecystectomy; CPM, cyclophosphamide; D, distal; DOX, doxorubicin; Exc of BD, excision of bile duct; Ext lt hep, extended light hepatic lobectomy; Ext rt hep, extended right hepatic lobectomy; FM, fibromuscular; GEM, gemcitabine; GJ, gastrojejunostomy; LN, lymph node; M, metachronous; Mod, moderately differentiated type; MTX, methotrexate; NA, not available; P, perihilar; PCZ, procarbazine; PD, pancreatoduodenectomy; Por, poorly differentiated type; PPPD, pylorus-preserving pancreatoduodenectomy; PV, portal vein; S, synchronous; SI, serosa infiltrating; SS, subserosa; SSPPD, subtotal stomach-preserving pancreatoduodenectomy; Well, well differentiated type.